Steven E McNulty
Overview
Explore the profile of Steven E McNulty including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
4719
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
OHalloran J, Ko E, Anstrom K, Kedar E, McCarthy M, Panettieri Jr R, et al.
JAMA
. 2023 Jul;
330(4):328-339.
PMID: 37428480
Importance: Immune dysregulation contributes to poorer outcomes in COVID-19. Objective: To investigate whether abatacept, cenicriviroc, or infliximab provides benefit when added to standard care for COVID-19 pneumonia. Design, Setting, And...
2.
Ko E, Anstrom K, Panettieri R, Lachiewicz A, Maillo M, OHalloran J, et al.
medRxiv
. 2022 Oct;
PMID: 36203544
Background: We investigated whether abatacept, a selective costimulation modulator, provides additional benefit when added to standard-of-care for patients hospitalized with Covid-19. Methods: We conducted a master protocol to investigate immunomodulators...
3.
OHalloran J, Kedar E, Anstrom K, McCarthy M, Ko E, Nunez P, et al.
medRxiv
. 2022 Sep;
PMID: 36172138
Background: Immune dysregulation contributes to poorer outcomes in severe Covid-19. Immunomodulators targeting various pathways have improved outcomes. We investigated whether infliximab provides benefit over standard of care. Methods: We conducted...
4.
Vader J, Givertz M, Starling R, McNulty S, Anstrom K, Desvigne-Nickens P, et al.
JACC Heart Fail
. 2022 Jun;
10(7):449-456.
PMID: 35772853
Background: The LIFE (LCZ696 In Hospitalized Advanced Heart FailurE) trial, which evaluated sacubitril/valsartan in patients with advanced heart failure (HF) with reduced ejection fraction and recent New York Heart Association...
5.
Mann D, Givertz M, Vader J, Starling R, Shah P, McNulty S, et al.
JAMA Cardiol
. 2021 Nov;
7(1):17-25.
PMID: 34730769
Importance: The use of sacubitril/valsartan is not endorsed by practice guidelines for use in patients with New York Heart Association class IV heart failure with a reduced ejection fraction because...
6.
Sharma A, Greene S, Vaduganathan M, Fudim M, Ambrosy A, Sun J, et al.
ESC Heart Fail
. 2021 Jun;
8(4):2608-2616.
PMID: 34061470
Aims: Associations between growth differentiation factor-15 (GDF-15), cardiovascular outcomes, and exercise capacity among patients with a recent hospitalization for heart failure (HHF) and heart failure with reduced ejection fraction (HFrEF)...
7.
Mann D, Greene S, Givertz M, Vader J, Starling R, Ambrosy A, et al.
JACC Heart Fail
. 2020 Jul;
8(10):789-799.
PMID: 32641226
The PARADIGM-HF (Prospective Comparison of Angiotensin II Receptor Blocker Neprilysin Inhibitor With Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure) trial reported that sacubitril/valsartan...
8.
Redouane B, Greene S, Fudim M, Vaduganathan M, Ambrosy A, Sun J, et al.
Circ Heart Fail
. 2020 May;
13(5):e006758.
PMID: 32362166
Background: The FIGHT (Functional Impact of GLP-1 [glucagon-like peptide-1] for Heart Failure Treatment) trial randomized 300 patients with heart failure with reduced ejection fraction (HFrEF) and a recent hospitalization for...
9.
Armstrong P, Pieske B, Anstrom K, Ezekowitz J, Hernandez A, Butler J, et al.
N Engl J Med
. 2020 Mar;
382(20):1883-1893.
PMID: 32222134
Background: The effect of vericiguat, a novel oral soluble guanylate cyclase stimulator, in patients with heart failure and reduced ejection fraction who had recently been hospitalized or had received intravenous...
10.
Blumer V, Greene S, Sun J, Bart B, Ambrosy A, Butler J, et al.
Eur J Heart Fail
. 2019 Aug;
21(11):1472-1476.
PMID: 31452311
No abstract available.